
About Brawn Biotech
Brawn Biotech is a publicly listed company based in Delhi (India) founded in 1986. Pharmaceutical formulations are distributed across major healthcare segments. Its Indian entity Brawn Biotech Limited reported revenue of βΉ17.43 Cr. Brawn Biotech offers products and services including Antibacterials, Cardiovasculars, and Antidiabetics. Its focus areas include Pharmaceutical Distributors and Diversified. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.
Company details
Brawn Biotech Ltd. was founded in 1986 and operates as a fully integrated healthcare company based in Delhi, India. Presence is maintained in both domestic and international markets, with pharmaceutical formulations provided across a broad range of product segments. Operations focus on the Indian pharmaceutical industry, where market share is targeted through established distribution networks in the healthcare sector.
- Headquarters Delhi, India
- Stage Public
- SectorsHealthcare
- Website brawnbiotech.com
- Legal Name Brawn Biotech Limited
- Market Cap₹6.30 Cr
BRAWN · BSE
- Share Price₹20.99
-0.05% today
- Revenue₹16.98 Cr
FY 2025-26 · +26.2% YoY
- EBITDA−₹0.31 Cr
Margin -1.8%
- Net Profit₹0.96 Cr
FY 2025-26 · +155.2% YoY
- P/E (TTM)31.4x
P/B 2.0x
- ROE22.2%
ROCE 0.0%
Associated legal entities of Brawn Biotech
Brawn Biotech is associated with 2 registered companies on The Company Check; the primary company is Brawn Biotech Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Brawn Biotech Limited Listed CIN L74899DL1985PLC022468 | Active | 07 Nov 1985 | Delhi, Delhi | ₹17.4 Cr | 17 | 5 | View details |
| Overseas Laboratories Private Limited CIN U51397DL2003PTC120157 | Strike Off | 02 May 2003 | New Delhi, Delhi | 2 | View details |
Products & Services of Brawn Biotech
Brawn Biotech offers a comprehensive portfolio of products and services, including Antibacterials, Cardiovasculars, and Antidiabetics.
Medications for treating bacterial infections effectively.
Drugs for managing heart and blood vessel conditions.
Treatments for controlling blood sugar levels in diabetes.
Board of directors of Brawn Biotech Limited (Brawn Biotech)
Brawn Biotech Limited is the primary company behind Brawn Biotech. The boards of the 2 registered companies of Brawn Biotech currently have 4 directors; the longest-serving is Adarsh Kumar Gupta, appointed in 2003. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Adarsh Kumar Gupta DIN 00975059 | Director | 02 May 2003 | 23 yrs 6 mo | Overseas Laboratories Private Limited |
| Brij Raj Gupta DIN 00974969 | Director | 02 May 2003 | 23 yrs 6 mo | Overseas Laboratories Private Limited, Brawn Biotech Limited |
| Mayank Jain DIN 07993851 | Director | 27 Aug 2024 | 2 yrs 2 mo | Brawn Biotech Limited |
| Pooja Jha DIN 10749145 | Director | 27 Aug 2024 | 2 yrs 2 mo | Brawn Biotech Limited |
IPO & Listings of Brawn Biotech
Brawn Biotech is a publicly listed company on the BSE with ticker symbol BRAWN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 May 1995
- Listed onBSE: 530207
- Listed entityBrawn Biotech Limited
- Exchange sectorHealth technology
- ISININE899B01015
- Share price₹23.30 · 2026-10-14
- Market capitalisation₹7.0 Cr
- Price to earnings8.1
- EPS (diluted, trailing year)₹2.86
- Volume (last session)26
Financials of Brawn Biotech
Exchange-reported figures of Brawn Biotech Limited, the listed company behind Brawn Biotech (BSE: BRAWN).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Balance sheet | |||||||
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Net worth | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Cash flow | |||||||
| Cash from operations | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Cash from investing | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| Other income | 0.45 | 0.09 | 0.09 | 0.01 | 0.00 | 0.31 | 0.17 |
| Total expenses | 17.29 | 15.24 | 17.96 | 22.52 | 10.62 | 35.57 | 48.88 |
| Employee cost | 0.68 | 1.13 | 1.40 | 1.40 | 1.80 | 2.36 | 3.08 |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Depreciation | 0.12 | 0.11 | 0.10 | 0.11 | 0.05 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.06 | 0.01 | 0.06 | 0.04 | 0.05 |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Tax | (0.94) | (0.06) | (0.30) | 0.45 | (0.47) | 0.20 | 0.23 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves & surplus | 1.34 | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | 6.26 |
| Shareholders' funds (net worth) | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Assets | |||||||
| Gross block | 1.05 | 1.02 | 0.78 | 0.77 | 0.67 | 0.38 | 0.38 |
| Net block | 0.36 | 0.46 | 0.33 | 0.37 | 0.38 | 0.14 | 0.18 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.06 | 10.47 | 6.02 | 4.79 | 4.72 | 0.26 | 0.39 |
| Sundry debtors | 3.55 | 3.41 | 3.88 | 5.32 | 2.81 | 9.28 | 15.00 |
| Cash & bank balances | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Loans & advances | 3.23 | 3.43 | 2.84 | 2.85 | 4.43 | 2.79 | 3.42 |
| Total current assets | 17.12 | 17.51 | 13.14 | 13.40 | 12.18 | 12.73 | 19.21 |
| Total current liabilities | 15.17 | 9.33 | 6.51 | 8.05 | 6.32 | 4.90 | 10.92 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.20 | 0.00 | 0.44 | 0.22 | 0.40 | 0.40 | 0.54 |
| Net cash from operating activities | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Net cash from investing activities | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Net change in cash | 0.74 | (0.20) | (0.04) | 0.21 | (0.17) | 0.00 | (0.14) |
| Closing cash | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA growth | +82.6% | -21.1% | -406.9% | +85.5% | -239.0% | -179.7% | - |
| PBT growth | +9998.0% | -16.9% | -285.0% | +81.0% | -502.9% | - | -54.4% |
| Net income growth | +155.2% | -41.5% | -44.7% | +48.2% | -198.2% | -191.7% | - |
| Revenue CAGR (3Y) | -8.6% | +16.0% | -22.2% | -23.5% | -49.1% | -14.4% | -6.4% |
| EBITDA CAGR (3Y) | +2.3% | -3.8% | +35.6% | - | - | - | -15.6% |
| Profitability & leverage | |||||||
| Net income margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| Return on capital employed | 0.0% | 0.0% | -20.5% | -5.7% | -25.0% | -3.5% | +9.6% |
| Return on net worth | +22.2% | 0.0% | -22.0% | -12.9% | -20.5% | -6.1% | +6.6% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -3.82 | -2.50 | -2.93 | -6.45 | 7.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.41 | 14.96 | 21.28 | 30.88 | 16.42 | 92.05 | 132.32 |
| Inventory turnover | 1.65 | 1.63 | 3.05 | 4.68 | 3.46 | 107.63 | 135.95 |
| Debtors turnover | 4.88 | 3.69 | 3.58 | 5.47 | 1.43 | 2.88 | 3.15 |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 14.46 | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | 30.87 |
Similar companies to Brawn Biotech
Brawn Biotech has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enterohealthcare.com | 2018 | Mumbai, India | $59.67M | 817 | India's leading healthcare products distribution platform | |
| keimed.com | 2000 | Hyderabad, India | $16.62M | 588 | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | |
| sandor.co.in | 1995 | Hyderabad, India | $8.98M | 161 | Provider of medical equipment, devices, and drugs distribution services |
Detailed similar companies of Brawn Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Brawn Biotech
The website of Brawn Biotech (brawnbiotech.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 22.1% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brawn Biotech
Complete news archive for Brawn Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brawn Biotech
Brawn Biotech was founded in 1986.
Brawn Biotech is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
The primary company behind Brawn Biotech, Brawn Biotech Limited, reported revenue of βΉ17.43 Cr for FY 2026, up 26% year on year.
Brawn Biotech Ltd. was founded in 1986 and operates as a fully integrated healthcare company based in Delhi, India. Presence is maintained in both domestic and international markets, with pharmaceutical formulations provided across a broad range of product segments. Operations focus on the Indian pharmaceutical industry, where market share is targeted through established distribution networks in the healthcare sector.
Brawn Biotech's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.
Brawn Biotech offers Antibacterials, Cardiovasculars, and Antidiabetics.
Yes, Brawn Biotech is publicly traded on BSE under the ticker symbol BRAWN.
Brawn Biotech is associated with 2 legal entities: Brawn Biotech Limited, Overseas Laboratories Private Limited.
The legal entities of Brawn Biotech currently have 6 directors, including Adarsh Kumar Gupta, Brij Raj Gupta, Priyanka Sharma and others.
